when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

BRISTOL · news · pharmadog

← back to BRISTOL

News mentioning BRISTOL

354 stories

Sep 11, 26BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readoutfiercebiotech

Sep 10, 26In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacyfiercebiotech

Sep 10, 26Chutes & Ladders—Longtime Takeda R&D chief to depart next Junefiercebiotech

Sep 10, 26STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and morestat

Sep 10, 26STAT+: Cancer medicines remain in short supply across the U.S., survey findsstat

Sep 10, 26Tyra shares slip as bladder cancer responses fall short of investor expectationsbiospace

Sep 9, 26CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’fiercebiotech

Sep 9, 26STAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and morestat

Sep 9, 26BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’biospace

Sep 9, 26Beeline Medicines reports promising Phase 2 lupus dataendpoints

Sep 9, 26A new immuno-oncology play raises $225M for a next-generation drugbiopharma dive

Sep 9, 26Beeline flies into phase 3 as oral lupus drug soars past placebofiercebiotech

Sep 9, 26Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2fiercebiotech

Sep 8, 26Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapybiopharma dive

Sep 8, 26STAT+: FDA warns an API supplier about residue on walls, a corroded product line, and open-toed sandalsstat

Sep 8, 26Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-Tendpoints

Sep 8, 26STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and morestat

Sep 8, 26Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpointfiercebiotech

Sep 8, 26AI will only revolutionize drug discovery and development if we play to its strengthsbiospace

Sep 4, 26Biotech is back, with H1 progress smoothing glide path through end of year: Truistbiospace

Sep 4, 26STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and morestat

Sep 3, 26STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and morestat

Sep 3, 26Akeso, Summit cancer drug confirms lung cancer survival benefitbiopharma dive

Sep 3, 26Replimune’s melanoma drug would have been rejected again if not for senior CBER officialbiospace

Sep 3, 26AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialfiercebiotech

Sep 3, 26GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer assetfiercebiotech

Sep 2, 26Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study haltsbiopharma dive

Sep 2, 26Novartis telegraphs 130 job cuts amid biologics rethink in Switzerlandfiercebiotech

Sep 2, 26STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and morestat

Sep 2, 26Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsbiospace

← prevpage 5 of 12next →